Adamas Pharmaceuticals, Inc. (ADMS): Price and Financial Metrics


Adamas Pharmaceuticals, Inc. (ADMS)

Today's Latest Price: $4.23 USD

0.07 (-1.63%)

Updated Sep 25 4:00pm

Add ADMS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ADMS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ADMS is -2.6 -- better than just 3.68% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -28.97 for Adamas Pharmaceuticals Inc; that's greater than it is for merely 0.84% of US stocks.
  • As for revenue growth, note that ADMS's revenue has grown 31.63% over the past 12 months; that beats the revenue growth of 85.33% of US companies in our set.
  • Stocks that are quantitatively similar to ADMS, based on their financial statements, market capitalization, and price volatility, are NEOS, TXMD, LAIX, AQST, and MNKD.
  • ADMS's SEC filings can be seen here. And to visit Adamas Pharmaceuticals Inc's official web site, go to www.adamaspharma.com.
ADMS Daily Price Range
ADMS 52-Week Price Range

ADMS Stock Price Chart Technical Analysis Charts


ADMS Price/Volume Stats

Current price $4.23 52-week high $7.50
Prev. close $4.30 52-week low $1.90
Day low $4.21 Volume 140,000
Day high $4.47 Avg. volume 481,159
50-day MA $4.13 Dividend yield N/A
200-day MA $3.81 Market Cap 119.63M

Adamas Pharmaceuticals, Inc. (ADMS) Company Bio


Adamas Pharmaceuticals is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company was founded in 2000 and is based in Emeryville, California.


ADMS Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMS Latest Social Stream


Loading social stream, please wait...

View Full ADMS Social Stream

Latest ADMS News From Around the Web

Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 269,250 shares of the company’s common stock, at a per share exercise price of $5.12, the closing trading price on September 8, and restricted stock units to acquire 2,125 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment...

Yahoo | September 11, 2020

Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress

EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020. “These presentations provide further evidence that GOCOVRI may reduce OFF time for people with Parkinson’s, with prolonged effects for at least two years,” said Jean Hubble MD, Vice President, Medical Affairs at Adamas. “Both dyskinesia and OFF disrupt daily activities fo...

Yahoo | September 11, 2020

Adamas to Present at Upcoming HC Wainwright Conference

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time (9:30 am Pacific). The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentation.About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to...

Yahoo | September 8, 2020

Adamas Appoints Anna Richo to Board of Directors

EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc., to its Board of Directors. She will also serve on the Audit Committee. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, Amgen, and Baxter Healthcare as well as prior public-company Board, Audit, and Finance Committee experience at Cytyc Corporation. “We are delighted to welcome Anna to our board during t...

Yahoo | September 1, 2020

What Kind Of Shareholders Own Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)?

The big shareholder groups in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) have power over the company. Insiders often...

Yahoo | August 21, 2020

Read More 'ADMS' Stories Here

ADMS Price Returns

1-mo -17.38%
3-mo 68.53%
6-mo 46.37%
1-year -36.53%
3-year -79.69%
5-year -74.16%
YTD 11.61%
2019 -55.62%
2018 -74.80%
2017 100.53%
2016 -40.32%
2015 63.04%

Continue Researching ADMS

Here are a few links from around the web to help you further your research on Adamas Pharmaceuticals Inc's stock as an investment opportunity:

Adamas Pharmaceuticals Inc (ADMS) Stock Price | Nasdaq
Adamas Pharmaceuticals Inc (ADMS) Stock Quote, History and News - Yahoo Finance
Adamas Pharmaceuticals Inc (ADMS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8734 seconds.